HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine

HCID 1388
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
28289-54-5
Standard SMILES
CN1CC=C(c2ccccc2)CC1
InChIKey
PLRACCBDVIHHLZ-UHFFFAOYSA-N
Molecular formula
C12H15N
Average molar mass
173.25 g/mol
Monoisotopic mass
173.12044948

Overview

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is a tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4. It has a role as a neurotoxin. It is a member of methylpyridines, a tetrahydropyridine and a phenylpyridine.

Names & identifiers

Preferred name
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
IUPAC
1-methyl-4-phenyl-3,6-dihydro-2H-pyridine
English name
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Molecular formula
C12H15N
Molecular weight
173.25

Names & synonyms

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine28289-54-5MPTPPYRIDINE, 1,2,3,6-TETRAHYDRO-1-METHYL-4-PHENYL-1,2,3,6-Tetrahydro-1-methyl-4-phenylpyridineDTXSID8040933N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine9P21XSP91PNSC-139654CHEBI:17963RefChem:76325DTXCID6020933
Show more names
NSC 139654Naphthoic Acid Impurity 1111-Methyl-4-phenyl-1,2,3,6-tetrahydropyridin1,2,3,6-tetrahydro-1-methyl-4-phenyl-pyridin1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDRO-PYRIDINEN-METHYL-4-PHENYL-1,2,3,6-TETRAHYDRO-PYRIDINE
248-939-71-methyl-4-phenyl-3,6-dihydro-2H-pyridine1-METHYL-4-PHENYL-PIPERIDINE-3-ENCCRIS 2186HSDB 6942CHEMBL241721-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine1-Methyl-4-phenyl-1,2,3,6-tetrahydroxpyridine

Database identifiers

CAS

Properties

Computed structural propertiesFilling in

XLogP
2.7
Topological polar surface area
3.2 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
1
Rotatable bonds
1
Heavy atoms
13
Formal charge
0
Complexity
189

Experimental & physicochemical properties

Chemical ClassesNitrogen Compounds -> Pyridines
DrugsDEA NFLIS-Drug Category -> Narcotics
LogPlog Kow = 2.71 @ pH 7.5 (as MPP+)
Color/FormCrystals from heptane
Boiling Point85 to 90 °C @ 0.8 mm Hg
Melting Point40-42 °C
Vapor Pressure0.00945 [mmHg]
Physical DescriptionCrystals; [HSDB]

Physicochemical properties

Melting point
36 °C · aprox. 36°C
Boiling point
128 · 128-132 °C12 mm Hg(lit.)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P260, P264, P270, P301+P316, P308+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazards Summary · 1 item

The toxic effects of MPTP were discovered in 1982 when several injection drug users in San Jose, California developed frozen addict syndrome within a week of using MPPP contaminated with MPTP. The syndrome resembled idiopathic Parkinson disease, and patients showed some improvement after treatment with L-dopa. [Ford, p. 634-5] MPTP does not cause occupational parkinsonism, but it causes acute parkinsonism in humans and experimental animals after injection. The cumulative doses in animals are in the range of 1.5 to 410 mg/kg depending on the species. [See Reference #1}

Hazard Classes and CategoriesAcute Tox. 3 (100%)

Safety & protection

Disposal Methods · 1 item

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Toxicology

Chemistry & industry

Pharmacology

Metabolism/Metabolites · 2 items

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has known human metabolites that include p-hydroxy-MPTP and 1-methyl-4-phenylpyridin-1-ium.

In the brain, MPTP is metabolized into the toxic cation 1-methyl-4-phenylpyridinium (MPP+) by the enzyme MAO-B of glial cells. (L1670)

MeSH Pharmacological Classification · 2 items

Toxic substances from microorganisms, plants or animals that interfere with the functions of the nervous system. Most venoms contain neurotoxic substances. Myotoxins are included in this concept.

Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.

Uses & manufacturing

Uses · 2 items

A contaminant produced during the synthesis of MPPP, a synthetic heroin; it causes irreversible parkinsonism in primates and is used in research laboratories; MPTP is converted to the toxic metabolite MPP+ in the brain where it selectively destroys cells in the substantia nigra. [Merck Index #6294]

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin that causes permanent symptoms of Parkinson's disease by killing certain neurons in the substantia nigra of the brain. MPTP can be accidentally produced during the illicit manufacture of MPPP, and that is how its Parkinson-inducing effects were first discovered. MPTP is used to recreate and study the Parkinson's disease in experimental animal models.

Methods of ManufacturingPrepn as hydrochloride by Grignard reaction: A Ziering et al, J Org Chem 12, 894 (1947). Alternative prepn: CJ Schmidle, RC Mansfield, J Am Chem Soc 78, 425 (1956).
General Manufacturing InformationIdentification as impurity in "synthetic heroin".

Applications

Related reactions

9 records
New reaction record
HRID 225222 reaction equation
HRID 225222As reactant
HRID 669905 reaction equation
HRID 669905As product
HRID 1277525 reaction equation
HRID 1277525As reactant
HRID 1568962 reaction equation
HRID 1568962As reactant
HRID 1980093 reaction equation
HRID 1980093As reactant
HRID 2134151 reaction equation
HRID 2134151As reactant
HRID 2150391 reaction equation
HRID 2150391As reactant
HRID 2163137 reaction equation
HRID 2163137As product
PreviousPage 1 of 2

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
28289-54-5
PubChem CID
1388
DTXSID
DTXSID8040933
ChEMBL
CHEMBL24172
ChEBI
CHEBI:17963
UNII
9P21XSP91P
EC Number
248-939-7
Nikkaji
J22.909A
Density
1.001 · 1.001±0.06 g/cm3(Predicted)
storage temp.
Inert atmosphere,Room Temperature
solubility
Chloroform (Slightly), Dichloromethane (Slightly), Ethyl Acetate (Slightly)
pka
8.66 · 8.66±0.40(Predicted)
form
Solid
color
Pale Yellow to Light Yellow
Merck
13 · 13,6319
Stability
Stable. Incompatible with strong oxidizing agents.
FDA UNII
9 P21XSP91P · 9P21XSP91P
Symbol(GHS)
8 · GHS08,GHS06
Signal word
Danger
Hazard statements
370 · H370-H301
Precautionary statements
264 · P264-P270-P301+P310-P321-P330-P405-P501-P260-P264-P270-P307+P311-P321-P405-P501
Hazard Codes
T
Risk Statements
25 · 25-39/23/24/25
Safety Statements
45 · 45
RIDADR
2811 · UN 2811 6.1/PG 2
WGK Germany
3 · 3
RTECS
8358900 · UT8358900
HazardClass
6.1 · 6.1(b)
PackingGroup
III
Hazardous Substances Data
28289 · 28289-54-5(Hazardous Substances Data)
Toxicity
1 · Human toxicity originally discovered when it was an unexpected by-product from the illicit synthesis of a heroin substitute (i.e., meperidine analog). Currently used experimentally as the primary animal model for the study of Parkinson’s disease. MPTP is a neurotoxicant that is activated to 1-methyl-4-phenylpyridinium ion (MPP1) by the actions of monoamine oxidase B located in the mitochondria of brain astrocytes. The MPP1 is then transported into dopamine, and to a lesser extent, other monoaminergic neurons. Once inside these dopamine neurons in the substantia nigra, it destroys these neurons by mechanisms that may involve an oxidative cascade and/or inhibition of electron transport. Intoxication causes a parkinsonism syndrome almost identical in signs and symptoms to Parkinson’s disease, including rigidity, bradykinesia, tremor, and postural instability. In the event of known ingestion, immediate (but not delayed) administration of a monoamine oxidase inhibitor (especially one selective for MAO-B like deprenyl) and dopamine uptake inhibitor can be therapeutic.
Treatment · 1 item

Because MPTP itself is not directly harmful, toxic effects of acute MPTP poisoning can be mitigated by the administration of monoamine oxidase inhibitors (MAOIs) such as selegiline. MAOIs prevent the metabolism of MPTP to MPP+ by inhibiting the action of MAO-B, minimizing toxicity and preventing neural death. (L1670)

Adverse EffectsNeurotoxin - Parkinsonism
Toxicity Summary · 1 item

MPTP itself is not toxic, and as a lipophilic compound can cross the blood-brain barrier. Once inside the brain, MPTP is metabolized into the toxic cation 1-methyl-4-phenylpyridinium (MPP+) by the enzyme MAO-B of glial cells. MPP+ primarily kills dopamine-producing neurons in a part of the brain called the pars compacta of the substantia nigra. MPP+ interferes with complex I of the electron transport chain, a component of mitochondrial metabolism, which leads to cell death and causes the buildup of free radicals, toxic molecules that contribute further to cell destruction. (L1670)

Human Toxicity Excerpts · 1 item

chemical selective damage to cells in the substantia nigra occurs following human ingestion of MPTP (1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine). ... Following iv injection of an illicit drug containing MPTP, humans developed chronic Parkinsonism, resulting from substantia nigra destruction.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Antidote and Emergency Treatment · 2 items

/SRP:/ Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poison A and B/

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in respiratory arrest. Positive pressure ventilation techniques with a bag valve mask device may be beneficial. Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start an IV with D5W /SRP: "To keep open", minimal flow rate/. Use lactated Ringer's if signs of hypovolemia are present. Watch for signs of fluid overload. Consider drug therapy for pulmonary edema ... . For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam (Valium) ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poison A and B/

Toxicity DataLD50: 54 mg/kg (Subcutaneous, Mouse) (A2830)

Safety data

wgk
3
rtecs
UT8358900
ridadr
UN 2811 6.1/PG 2
Toxicity
Human toxicity originally discovered when it was an unexpected by-product from the illicit synthesis of a heroin substitute (i.e., meperidine analog). Currently used experimentally as the primary animal model for the study of Parkinson’s disease. MPTP is a neurotoxicant that is activated to 1-methyl-4-phenylpyridinium ion (MPP1) by the actions of monoamine oxidase B located in the mitochondria of brain astrocytes. The MPP1 is then transported into dopamine, and to a lesser extent, other monoaminergic neurons. Once inside these dopamine neurons in the substantia nigra, it destroys these neurons by mechanisms that may involve an oxidative cascade and/or inhibition of electron transport. Intoxication causes a parkinsonism syndrome almost identical in signs and symptoms to Parkinson’s disease, including rigidity, bradykinesia, tremor, and postural instability. In the event of known ingestion, immediate (but not delayed) administration of a monoamine oxidase inhibitor (especially one selective for MAO-B like deprenyl) and dopamine uptake inhibitor can be therapeutic.
risk_code
25-39/23/24/25
Signal word
Danger
Symbol(GHS)
GHS08,GHS06
hazard_code
T
safety_code
45
hazard_class
6.1(b)
packing_group
III
Hazard statements
H370-H301
Precautionary statements
P264-P270-P301+P310-P321-P330-P405-P501-P260-P264-P270-P307+P311-P321-P405-P501
Hazardous Substances Data
28289-54-5(Hazardous Substances Data)

Uses1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine is a dopaminergic neurotoxin that reportedly causes a severe and irreversible Parkinsonian condition in humans and monkeys.

Additional notes

DefinitionChEBI: A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.